Quan Nguyen
Allergy · Newark, DENPI 1144258120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,344 and has fallen 81.9% since, to $425 in 2023.
Across 251 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$919
- Regeneron Healthcare Solutions, Inc.$701
- GSK$562
- Sanofi$446
- Genentech USA, Inc.$400
- Biocryst US Sales Co., LLC$296
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,382100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $919 |
| Regeneron Healthcare Solutions, Inc. | 29 | $701 |
| GSK | 32 | $562 |
| Sanofi | 15 | $446 |
| Genentech USA, Inc. | 16 | $400 |
| Biocryst US Sales Co., LLC | 12 | $296 |
| Pfizer | 13 | $214 |
| Optinose US, Inc. | 8 | $212 |
| CSL Behring | 13 | $199 |
| AbbVie | 11 | $191 |
| Pharming Healthcare, Inc. | 12 | $184 |
| Octapharma USA, Inc. | 1 | $182 |
| Alk-abello, Inc | 10 | $160 |
| Kaleo, Inc. | 9 | $136 |
| Novartis | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $105 |
| Grifols USA, LLC | 4 | $69 |
| Covis Pharma GmbH | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Boehringer Ingelheim | 2 | $34 |
| Bio Products Laboratory USA, Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Amgen(2 entities) | 2 | $27 |
| Aerin Medical Inc. | 1 | $21 |
| Greer Laboratories, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Biocryst Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Delawareto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $69,820 |
| Azelastine Hcl | 11 | $419 |
| Fluticasone Propionate | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Other allergy in Newark
- William GeimeierNewark$627
- Shankar LakhaniDover$5K
- Joel TempleDover$41
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.